Market Overview:
A biopsy is a small operation that is used to
perform the removal of tissues from an area of concern from the body. Breast
biopsy is a medical procedure that involves the testing of small samples of
breast tissues for the detection of breast cancer. This form of biopsy is
conducted with the help of minimally invasive biopsy systems due to minimal
pain and disfigurement. There are various types of biopsy procedures that are
used depending upon the different techniques like vacuum-assisted biopsy (VAB),
core needle biopsy (CNB ), and fine
needle aspiration biopsy (FNAB). These are recommended by the doctor based on
the size, location, and other characteristics of the breast abnormality.
The global Breast
Biopsy Market Statistics is expected
to expand in significant fashion during the forecast period of 2018 to 2023.The
growing prevalence of breast cancer among women is the major driver for the
global breast imaging market. Breast cancer is the second most prevalent
type of cancer among women, with more than 200,000 new cases diagnosed every
year. Breast cancer has also become a major public issue in recen tyears, with
a number of healthcare organizations and celebrities joining the cause to
promote breast cancer and raise funds for poor patients and further
product development to make breast imaging easier and more accurate. The
growing demand for precise diagnostic tools that can diagnose
breast cancer at an early stage is likely to be a major driver for the
global breast imaging market over the forecast period. Early diagnosis of
cancer is highly important in managing the disease and ensuring a positive
prognosis, leading to a growing demand for product development in the breast
imaging markettargeted at developing devices that can detect tumors when they
are at their smallest.
Competitive Landscape
·
Cook Medical Incorporated
·
Dickinson and Company
·
NuVue Therapeutics
·
Argon Medical Devices
·
Johnson & Johnson
·
Encapsule Medical Devices LLC
·
Leica Biosystems
·
R. Bard Inc
·
Argon Medical Devices
·
Hologic Inc
·
Devicor Medical Products Inc
·
Becton
·
Hologic Inc
Market Segmentation
·
The global breast biopsy market segmentation is done as per
technique type, product, guidance technology, and end-user.
·
By product, the market includes biopsy tables, guidance systems,
biopsy needles, biopsy wires, and others.
·
By technique type, the market includes core needle biopsy, fine
needle aspiration biopsy, wire localization, MRI-guided core needle biopsy,
biopsy markers, surgical biopsy, and sentinel node biopsy.
·
By guidance technology, the market includes CT-guided biopsy,
ultrasound-guided, mammography-guided magnetic resonance, and various other
image-guided breast biopsy (PET and thermography).
·
By end-user, the market comprises of ambulatory surgical centers,
hospitals, diagnostic centers, and others.
Regional Analysis
The geographical breast biopsy market
segmentation covers four major regions, namely North America, Asia-Pacific,
Europe, and the Middle East & Africa.
North America is anticipated to hold the largest
market share over the forecast period as per the market report published by
MRFR. This is primarily due to the early adoption of advanced medical
technologies and a continued emphasis on the development from companies
operating in cancer diagnostics. The Europe market holds the second-largest
share of the breast biopsy market due to the striking prevalence of breast
cancer in the UK and Belgium. Both North America and Europe comprise more than
50% of the of the global breast biopsy market share.
The regional market of Asia-Pacific is also
slated to experience a period of growth in the forthcoming years. This is
because of the demand for advanced technology, better rate of adoption of such
technologies, access to optimal treatment facilities, increasing favorable
initiatives undertaken by the government, and rising healthcare expenditure.
Lastly, the Middle East & Africa region is
expected to garner the least market growth due to the presence of an
underdeveloped healthcare industry, poor medical facilities, and lack of
technical proficiency and knowledge concerning the operation.
October 30th, 2019, a team from ETH
Zurich with support from the Swiss National Science Foundation developed a new
ultrasound method to help differentiate benign breast tumors from the malignant
ones. The clinical trials have proven to show great promise in the detection of
breast cancer and can be revolutionary in the medical segment for detecting
breast cancer.
No comments:
Post a Comment